Zobrazeno 1 - 10
of 442
pro vyhledávání: '"TREATMENT POLICY"'
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102477- (2024)
Summary: Background: It remains uncertain whether cultural engagement positively influences the reduction of pain risk, particularly depending on the social isolation status. The aim of this study was to examine the impact of cultural engagement on t
Externí odkaz:
https://doaj.org/article/71f995d7a38e4c439d3482ef7e7b4f39
Autor:
Olugbenga Ayodeji Mokuolu, Oladimeji Akeem Bolarinwa, Oluwatumobi Racheal Opadiran, Hafsat Abolore Ameen, Mehul Dhorda, Phaik Yeong Cheah, Chanaki Amaratunga, Freek de Haan, Paulina Tindana, Arjen M. Dondorp
Publikováno v:
Malaria Journal, Vol 22, Iss 1, Pp 1-13 (2023)
Abstract Background Recent reports of artemisinin partial resistance from Rwanda and Uganda are worrisome and suggest a future policy change to adopt new anti-malarials. This is a case study on the evolution, adoption, and implementation of new anti-
Externí odkaz:
https://doaj.org/article/29e39db799f94f25b9418b998918a5a1
Autor:
Tefa Kaisara, Farai Nyabadza
Publikováno v:
Mathematical Biosciences and Engineering, Vol 20, Iss 1, Pp 1122-1147 (2023)
The management of HIV/AIDS has evolved ever since advent of the disease in the past three decades. Many countries have had to revise their policies as new information on the virus, and its transmission dynamics emerged. In this paper, we track the ch
Externí odkaz:
https://doaj.org/article/38ff105b50e54559b2c3a628b9d9faa9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Evaluation of new treatment policies is often costly and challenging in complex conditions, such as hepatitis C virus (HCV) treatment, or in limited-resource settings. We sought to identify hypothetical policies for HCV treatment
Externí odkaz:
https://doaj.org/article/cb7e88a544ed4243bf5fb7fde551779f
Autor:
Shuai Wang, Haoyan Hu
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background In the past few decades various methods have been proposed to handle missing data of clinical studies, so as to assess the robustness of primary results. Some of the methods are based on the assumption of missing at random (MAR) w
Externí odkaz:
https://doaj.org/article/4be2e48ea0fa4b8abd2c3fba1d2ba93d
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
ObjectivesBased on the background of the implementation of graded diagnosis and treatment policy (GDT) in China, this paper studied the service optimization of primary medical institutions from the perspective of the primary medical treatment rate.Me
Externí odkaz:
https://doaj.org/article/9943465ee1284d3ead7eba93d821acd3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ying Huang, Nima S. Hejazi, Bryan Blette, Lindsay N. Carpp, David Benkeser, David C. Montefiori, Adrian B. McDermott, Youyi Fong, Holly E. Janes, Weiping Deng, Honghong Zhou, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Britta Flach, Bob C. Lin, Sarah O’Connell, Charlene McDanal, Amanda Eaton, Marcella Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Avi Kenny, Marco Carone, Chuong Huynh, Jacqueline Miller, Hana M. El Sahly, Lindsey R. Baden, Lisa A. Jackson, Thomas B. Campbell, Jesse Clark, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Rolando Pajon, Dean Follmann, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert, on behalf of the Immune Assays, Moderna, Inc., Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE), United States Government (USG)/CoVPN Biostatistics Teams
Publikováno v:
Viruses, Vol 15, Iss 10, p 2029 (2023)
The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing a
Externí odkaz:
https://doaj.org/article/86848c63770d47f1b9459f59b793650a